These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1002 related articles for article (PubMed ID: 15078990)

  • 1. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
    BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
    Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
    Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
    Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
    J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
    Engelman JA; Jänne PA; Mermel C; Pearlberg J; Mukohara T; Fleet C; Cichowski K; Johnson BE; Cantley LC
    Proc Natl Acad Sci U S A; 2005 Mar; 102(10):3788-93. PubMed ID: 15731348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
    Tanno S; Ohsaki Y; Nakanishi K; Toyoshima E; Kikuchi K
    Oncol Rep; 2004 Nov; 12(5):1053-7. PubMed ID: 15492792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
    Nishimura Y; Yoshioka K; Bereczky B; Itoh K
    Mol Cancer; 2008 May; 7():42. PubMed ID: 18492291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
    Teraishi F; Kagawa S; Watanabe T; Tango Y; Kawashima T; Umeoka T; Nisizaki M; Tanaka N; Fujiwara T
    FEBS Lett; 2005 Aug; 579(19):4069-75. PubMed ID: 16023108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling.
    Huang Y; Kim SO; Jiang J; Frank SJ
    J Biol Chem; 2003 May; 278(21):18902-13. PubMed ID: 12642595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
    Tung CL; Jian YJ; Syu JJ; Wang TJ; Chang PY; Chen CY; Jian YT; Lin YW
    Exp Cell Res; 2015 May; 334(1):126-35. PubMed ID: 25662161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
    Nishimura Y; Bereczky B; Ono M
    Histochem Cell Biol; 2007 May; 127(5):541-53. PubMed ID: 17361439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1/2 activation.
    Sah JF; Eckert RL; Chandraratna RA; Rorke EA
    J Biol Chem; 2002 Mar; 277(12):9728-35. PubMed ID: 11788593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.